Optibodies™: optimized monoclonal antibodies for IHC

Nordic BioSite’s GLP-compliant histology laboratory has developed a range of Optibodies™: monoclonal antibodies that are optimized for immunohistochemistry (IHC).Optibodies overcome a basic problem for pharma and biotech companies – that while high-affinity monoclonal antibodies play a vital role in many different kinds of research, large-quantity production of IHC-optimized antibodies can be time consuming and expensive.

The tailored BioSiteHisto Laboratory facilities and experienced researchers are ideal for production, purification, and modification of specialized monoclonal antibodies, allowing generation of high quality and target specific antibodies.

Antibody optimization

For BioSiteHisto, antibody optimization is a process in which pretreatment methods, antibody dilution, incubation times, blocking and detection conditions are fine tuned for each antibody under controlled laboratory conditions, measuring values of specificity, sensitivity and stability.

A key success factor is to select correct tissues to express antigens that are appropriately fixed and processed for the specified primary antibody. This is complex because even weakly expressing tissues are relevant, since they offer important information about sensitivity, specificity and signal to noise ratio.

Optimization of antibodies should always be performed with more than one antibody against the same tissue antigen to get results for comparison. Different pretreatment methods are used to fine tune antibody concentration and incubation times. This also helps avoiding one of the biggest challenges in successful optimization, the variations in staining results produced within a laboratory or between different laboratories.

Optibodies

BioSiteHisto-developed Optibodies™ are a series of mouse monoclonal antibodies, specified for the most clinically and diagnostically important markers.

Optibodies are fine-tuned to current clinical needs of today`s laboratory and are also tested against NordiQC quality control standards for control tissues and staining criteria.

The key criterion for each Optibody™ is specificity and high affinity towards its target epitopes. The antibody is also tailored to be flexible and reliable in use, with high consistency between lots.

Additional antibody services

BioSiteHisto can optimize antibodies against human soft and hard tissues as well as rodents, xenograft tissues and other animal models, including rat, rabbit, chicken, goats and sheep.

As well as offering a wide range of ‘off the shelf’ monoclonal antibodies, BioSiteHisto can take on outsourced optimization of customer-specific antibodies, working from supplied slides and tissue sections.

Optibody range

Nordic BioSite’s range of IHC optimized mouse monoclonal Optibodies includes:

Name	Aliases	Species reactivity	Format	Sizes
AMACR	RACE, alpha-methylacyl-CoA racemase,	Human, mouse	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
Androgen receptor	KD, AIS, TFM, DHTR, SBMA, HYSP1, NR3C4, SMAX1, HUMARA, AR	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
Bcl2		human	Optibodies	100 μl, 1 ml, 7 ml
CD10	Calla, CD-10	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
CD14		human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
CD3	T3Z, CD3H, CD3Q, CD3Z, TCRZ, CD3-ZETA, CD247	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
CD31	Platelet endothelial cell adhesion molecule 1 , PECAM1	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
CD326	EPCAM, EP-CAM, ESA, KSA, M4S1, MK-1, DIAR5, EGP-2,EGP40, KS1/4, MIC18, TROP1, TACSTD1	human	Concentrate or ready-to-use Optibodies	1 ml, 7 ml
CD38	T10	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
CEA	Carcino Embryonic Antigen; CEA; CD66e; DKFZp781M2392; CEACAM5,	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
CK17	CK17, PC, K17, PC2, PCHC1, KRT17	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
CK18	CK-LMW, CYK18, KRT18	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
CK19	K19, K1CS, MGC15366, KRT19	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
CK20	KRT20, Cytokeratin-20, Cytokeratin 20, K20, Keratin 20, Keratin-20, KRT21, CK-20, Protein IT	human	Optibodies	100 μl
CK5	CK-HMW, DD, EBS2, KRT5A, KRT5, Keratin 5, Cytokeratin5	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
Desmin	DES	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
ECAD	UVO; CDHE; LCAM; Arc-1; CD324; CDH1	Human, canine, monkey, ovine	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
Endoglin	CD105; ENG, END, ORW, HHT1, ORW1, FLJ41744	human	Concentrate, Optibodies	100 μl, 1 ml, 7 ml
GCG	GLP1; GLP2; GRPP	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
HER2	NEU, NGL, TKR1, CD340, HER-2, HER-2/neu, ERBB2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
Ki67	KIA, Ki-67, MKI67	human, canine	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
MBP	MGC99675	human, rat	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
Melan A		human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
MLH1	FCC2, COCA2, HNPCC, hMLH1, HNPCC2, MGC5172	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
Napsin A		human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
p53	LFS1, TRP53, FLJ92943, TP53	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
p63a	P51B; KET; p63α; p63 alpha,	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
Pan Cytokeratin	CK, Keratin, pan CK	human, canine	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
PAX5	BSAP	human, canine	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
SMA	AAT6; ACTSA; ACTA2; Actin alpha 2, smooth muscle, aorta, major constituent of thin filament	Human, monkey	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
SYP	MRXSYP, SYP, Synaptophysin (p38)	human, rat	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml
Vimentin	FLJ36605, VIM	human	Concentrate or ready-to-use Optibodies	100 μl, 1 ml, 7 ml

 

Resources

Click on Optibodies: optimized monoclonal antibodies for IHC for more information.
Click on Nordic Biosite to contact the company directly.